Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
130.1 USD | -0.13% | +2.00% | +19.30% |
05-09 | Merck Says Health Canada Approve Keytruda Combination in Biliary Tract Carcinoma | MT |
05-09 | Sector Update: Health Care Stocks Steady Pre-Bell Thursday | MT |
Sales 2024 * | 64.11B 5,120B | Sales 2025 * | 68.6B 5,479B | Capitalization | 329B 26,309B |
---|---|---|---|---|---|
Net income 2024 * | 19.51B 1,558B | Net income 2025 * | 22.27B 1,778B | EV / Sales 2024 * | 5.43 x |
Net Debt 2024 * | 18.91B 1,510B | Net Debt 2025 * | 7.6B 607B | EV / Sales 2025 * | 4.91 x |
P/E ratio 2024 * |
16.8
x | P/E ratio 2025 * |
14.6
x | Employees | 71,000 |
Yield 2024 * |
2.38% | Yield 2025 * |
2.52% | Free-Float | 70.77% |
Latest transcript on Merck & Co., Inc.
1 day | +1.28% | ||
1 week | +2.00% | ||
Current month | +0.65% | ||
1 month | +2.61% | ||
3 months | +3.67% | ||
6 months | +28.28% | ||
Current year | +19.30% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 31/03/14 |
Director of Finance/CFO | 55 | 31/12/89 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 31/07/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 26/11/07 |
Pamela Craig
BRD | Director/Board Member | 67 | 31/08/15 |
Inge Thulin
BRD | Director/Board Member | 69 | 28/02/18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
14.34% | 0 M€ | +12.39% | - | |
5.61% | 0 M€ | +7.69% | - |
Date | Price | Change | Volume |
---|---|---|---|
10/05/24 | 130.1 | -0.13% | 5,722,627 |
09/05/24 | 130.2 | +0.52% | 9,216,740 |
08/05/24 | 129.6 | -0.64% | 6,659,121 |
07/05/24 | 130.4 | +2.20% | 6,682,316 |
06/05/24 | 127.6 | +0.05% | 6,551,962 |
Delayed Quote Nyse, May 10, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.30% | 329B | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B | |
-2.71% | 159B |
- Stock Market
- Equities
- MRK Stock